Propofol dose and efficacy of defibrillation testing during implantation of subcutaneous implantable cardioverter-defibrillators: A retrospective, single center cohort study.
S-ICD
anesthesia
defibrillation testing
implantation
propofol
subcutaneous implantable cardioverter-defibrillators
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
21
11
2022
received:
18
08
2022
accepted:
22
11
2022
pubmed:
30
11
2022
medline:
11
2
2023
entrez:
29
11
2022
Statut:
ppublish
Résumé
Defibrillation testing (DFT) is recommended during subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation. Previous studies analyzing the potential interference of propofol with defibrillation threshold are inconsistent. The purpose of this study was to analyze whether propofol affects DFT post S-ICD placement. All patients with S-ICD implantation between 01/2017 and 11/2020 at the University Heart Center Freiburg were retrospectively analyzed. Two groups were generated depending on the success of the first shock during DFT. Implantation characteristics and dose of anesthetics were analyzed. In 12 of the included 80 (15%) patients, first shock during DFT failed. The absolute dose of propofol was significantly higher in patients with first shock failure (median 653 mg [IQR 503-855]) compared to patients with first shock termination (376 mg [200-600]; p = 0.027). Doses of opioids and midazolam as well as type of anesthesia did not differ between the groups. A multivariable binary logistic regression analysis confirmed an independent association of first shock termination and propofol dose (per 100 mg: OR 0.73 (95% CI: 0.56-0.95); p = 0.021). There is an independent association of propofol dose and first shock failure in routine S-ICD defibrillation testing.
Substances chimiques
Propofol
YI7VU623SF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-428Informations de copyright
© 2022 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.
Références
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for Europe Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-2867. doi:10.1093/eurheartj/ehv316
Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944-953. doi:10.1161/CIRCULATIONAHA.113.003042
Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace. 2016;18:159-183. doi:10.1093/europace/euv411
Healey JS, Hohnloser SH, Glikson M, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet. 2015;385:785-791. doi:10.1016/S0140-6736(14)61903-6
van der Stuijt W, Quast ABE, Knops RE. Defibrillation testing during implantation of the subcutaneous implantable cardioverter-defibrillator: a necessary standard or becoming redundant? Neth Heart J. 2020;28:122-127. doi:10.1007/s12471-020-01448-4
Quast A-FBE, Baalman SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: the PRAETORIAN score. Heart Rhythm. 2019;16:403-410. doi:10.1016/j.hrthm.2018.09.029
Jacob S, Abraham AE, McKelvey G. Anaesthetic drugs and defibrillation threshold testing. Drugs. 2008;68:1921-1922. doi:10.2165/00003495-200868130-00012
Gerstein NS, Young A, Schulman PM, Stecker EC, Jessel PM. Sedation in the electrophysiology laboratory: a multidisciplinary review. J Am Heart Assoc. 2016;5:e003629. doi:10.1161/JAHA.116.003629
Babbs CF. Effect of pentobarbital anesthesia on ventricular defibrillation threshold in dogs. Am Heart J. 1978;95:331-337. doi:10.1016/0002-8703(78)90364-2
Wang M, Dorian P. Defibrillation energy requirements differ between anesthetic agents. J Electrophysiol. 1989;3:86-94. doi:10.1111/j.1540-8167.1989.tb01535.x
Gill RM, Sweeney RJ, Reid PR. The defibrillation threshold: a comparison of anesthetics and measurement methods. Pacing Clin Electrophysiol. 1993;16:708-714. doi:10.1111/j.1540-8159.1993.tb01649.x
Weinbroum AA, Glick A, Copperman Y, Yashar T, Rudick V, Flaishon R. Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: first report in humans. Anesth Analg. 2002;95:1147-1153. doi:10.1097/00000539-200211000-00004
Moerman A, Herregods L, Tavernier R, Jordaens L, Struys M, Rolly G. Influence of anaesthesia on defibrillation threshold. Anaesthesia. 1998;53:1156-1159. doi:10.1046/j.1365-2044.1998.00643.x
Cohen TJ, Chengot T, Quan C, Peller AP. Elevation of defibrillation thresholds with propofol during implantable cardioverter-defibrillator testing. J Invasive Cardiol. 2000;12:121-123.
Warpechowski P, dos Santos ATL, Pereira PJI, de Lima GG. Effects of propofol on the cardiac conduction system. Braz J Anesthesiol. 2010;60:438-444. doi:10.1016/S0034-7094(10)70054-4
Shannon K, Saltzman D, Li I, Mokszycki R, Galletta G. Ventricular tachycardia converts to sinus rhythm after administration of propofol. Am J Emerg Med. 2021;48:377.e1-377.e3. doi:10.1016/j.ajem.2021.04.028
Mulpuru SK, Patel DV, Wilbur SL, Vasavada BC, Furqan T. Electrical storm and termination with propofol therapy: a case report. Int J Cardiol. 2008;128:e6-e8. doi:10.1016/j.ijcard.2007.05.052
Thomson SJ, Yate PM. Bradycardia after propofol infusion. Anaesthesia. 1987;42:430. doi:10.1111/j.1365-2044.1987.tb03994.x
Miró Ò, de La Red G, Fontanals J. Cessation of paroxysmal atrial fibrillation during acute intravenous propofol administration. Anesthesiology. 2000;92:910. doi:10.1097/00000542-200003000-00061
Kannan S, Sherwood N. Termination of supraventricular tachycardia by propofol. Br J Anaesth. 2002;88:874-875.
Burjorjee JE, Milne B. Propofol for electrical storm; a case report of cardioversion and suppression of ventricular tachycardia by propofol. Can J Anaesth. 2002;49:973-977. doi:10.1007/BF03016886
Lai LP, Lin JL, Wu MH, et al. Usefulness of intravenous propofol anesthesia for radiofrequency catheter ablation in patients with tachyarrhythmias: infeasibility for pediatric patients with ectopic atrial tachycardia. Pacing Clin Electrophysiol. 1999;22:1358-1364. doi:10.1111/j.1540-8159.1999.tb00629.x
Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14:1456-1463. doi:10.1016/j.hrthm.2017.05.016
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363:36-44. doi:10.1056/NEJMoa0909545
Kerber RE, Grayzel J, Hoyt R, Marcus M, Kennedy J. Transthoracic resistance in human defibrillation. Circulation. 1981;63:676-682. doi:10.1161/01.cir.63.3.676
Heist EK, Belalcazar A, Stahl W, Brouwer TF, Knops RE. Determinants of subcutaneous implantable cardioverter-defibrillator efficacy. JACC: Clin Electrophysiol. 2017;3:405-414. doi:10.1016/j.jacep.2016.10.016
Do K, Chang P, Konecny T, et al. Predictors of elevated defibrillation threshold with the subcutaneous implantable cardioverter-defibrillator. J Innov Cardiac Rhythm Manag. 2017;8:2920-2929. doi:10.19102/icrm.2017.081203
Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs. 2008;68:607-630. doi:10.2165/00003495-200868050-00004